Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lucid Diagnostics (LUCD) Research & Development (2021 - 2025)

Lucid Diagnostics' Research & Development history spans 5 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Research & Development rose 18.58% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $5.7 million, down 5.24%, while the annual FY2025 figure was $5.7 million, 5.24% down from the prior year.
  • Research & Development reached $1.7 million in Q4 2025 per LUCD's latest filing, up from $1.3 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.5 million in Q4 2021 to a low of $1.3 million in Q2 2025.
  • Average Research & Development over 5 years is $2.0 million, with a median of $1.8 million recorded in 2021.
  • Peak YoY movement for Research & Development: soared 83.66% in 2022, then tumbled 46.89% in 2023.
  • A 5-year view of Research & Development shows it stood at $3.5 million in 2021, then fell by 29.87% to $2.4 million in 2022, then dropped by 21.46% to $1.9 million in 2023, then dropped by 24.24% to $1.5 million in 2024, then grew by 18.58% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for LUCD's Research & Development are $1.7 million (Q4 2025), $1.3 million (Q3 2025), and $1.3 million (Q2 2025).